SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
05 July 2022 - 10:00PM
SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a
clinical-stage biopharmaceutical company with a novel immunotherapy
platform that produces specifically targeted, high-potency, fully
human polyclonal antibodies without the need for human donors,
hosted U.S. Congressmen Dusty Johnson (R-SD) and Dean Phillips
(D-MN-3) on Friday, July 1, for a tour of SAB’s facilities and to
learn about SAB’s innovative immunotherapy platform that enables a
scalable and reliable production of polyclonal antibodies.
During their visit, Congressmen Johnson and Phillips toured
SAB’s Plasma Production Facility, featuring the company’s
transchromosomic (Tc) Bovine™—genetically engineered cattle—which
provide SAB’s fully human polyclonal antibodies for therapeutics.
The Congressmen also met with members of SAB’s management team to
discuss the company’s history in COVID-19 treatment development and
SAB’s current pipeline in influenza, oncology, and type 1
diabetes.
“We were pleased to host Congressmen Johnson and Phillips at
SAB. We are tremendously proud of the novel immunotherapy
technology we have developed here in South Dakota, and we were able
to show Congressmen Johnson and Phillips our state-of-the-art
Plasma Production Facility and our ability to quickly develop novel
therapeutics using polyclonal antibodies,” said Eddie J. Sullivan,
Ph.D., co-founder, President and Chief Executive Officer of SAB
Biotherapeutics. “We greatly appreciated the Congressmen’s time in
South Dakota, and it was a pleasure discussing SAB’s mission to
address unmet global health needs and bring critical therapies to
patients worldwide.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage,
biopharmaceutical company advancing a new class of immunotherapies
leveraging fully human polyclonal antibodies with a focus on
building a leading immune and autoimmune disorders pipeline. SAB
has applied advanced genetic engineering and antibody science to
develop transchromosomic (Tc) Bovine™ that produce fully human
antibodies targeted at specific diseases, including infectious
diseases such as COVID-19 and influenza, immune and autoimmune
disorders including type 1 diabetes and organ transplantation, and
cancer. SAB’s versatile DiversitAb™ platform is applicable to a
wide range of serious unmet needs in human diseases. It produces
natural, specifically targeted, high-potency, human polyclonal
immunotherapies. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio/ and follow SAB on Twitter and
LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, including the development and
efficacy of SAB-185, our influenza program and other discovery
programs, our cash runway into 2023 and potential future government
and third-party collaborations or funded programs.
These statements are based on the current expectations of SAB
and are not predictions of actual performance. These
forward-looking statements are provided for illustrative purposes
only and are not intended to serve as, and must not be relied on,
by any investor as a guarantee, an assurance, a prediction or a
definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict, will differ
from assumption and are beyond the control of SAB. A further
description of risks and uncertainties can be found in SAB’s Annual
Report on Form 10-K, quarterly reports on Form 10-Q, and other
periodic reports filed with the Securities and Exchange Commission,
all of which will be filed with the U.S. Securities and Exchange
Commission and available at https://www.sec.gov/
CONTACTS
Investor Relations:SABIR@westwicke.com
Media Relations:SABPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jun 2024 to Jul 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jul 2023 to Jul 2024